AASLD Consensus Expert Panel Statement on the Clinical Best Practice in Managing Liver Patients in Times of COVID-19 Pandemic

main-banner-img

COVID Patient

LIVERFASt™ can safely provide the complete liver assessment clinically needed, whether a COVID-19 patient has pre-existing conditions such as hepatitis B or C, NASH or Fatty Liver or even those with undiagnosed liver disease.

Fibronostics covid patients
Fibronostics covid patients

How LIVERFASt™ helps in COVID-19?

COVID-19 patients experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. For COVID-19 cases, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of COVID-19, direct effect of the virus, or a complicated disease course.

Three important liver conditions: fibrosis, inflammation and steatosis, must be considered in the overall assessment and monitoring of COVID-19 patients. LIVERFASt™ can safely provide the complete liver assessment clinically needed, whether a COVID-19 patient has pre-existing conditions such as hepatitis B or C, NASH or Fatty Liver or even those with undiagnosed liver disease.

LIVERFASt™ being a serum biomarker-based diagnostic test platform, provides a simple laboratory process of performing and generating the test results, avoiding any potential exposure of COVID-19 transmission and limiting unnecessary transport of patients to undergo imaging modalities (eg. Ultrasound, MRI, MRCP) in the radiology department as stated in the current AASLD 2020 clinical insights.

Learn more from

To learn more about integrating LIVERFASt™ in your organization